Biopsy Devices Market Summary
The global biopsy devices market size was estimated at USD 2.25 billion in 2023 and is projected to reach USD 3.64 billion by 2030, growing at a CAGR of 7.2% from 2024 to 2030. The market growth is primarily driven by the rising prevalence of cancer worldwide, increasing emphasis on minimally invasive surgical procedures, untapped opportunities in emerging economies, particularly in the Asia Pacific region, and the continuous improvement of healthcare infrastructure. Biopsy devices play a critical role in early and accurate disease diagnosis, guiding treatment decisions and improving patient outcomes.
According to the Union for International Cancer Control (UICC), more than 35 million new cancer cases are projected by 2050, representing an increase of approximately 77% from the estimated 20 million cases in 2022. This significant rise in cancer incidence is expected to fuel demand for biopsy devices, as early detection and precise tissue sampling become increasingly vital for effective treatment. The growing focus on minimally invasive procedures, which reduce patient recovery times and surgical risks, further supports market expansion, particularly in advanced healthcare systems.
Key Market Trends & Insights
- North America dominated the global biopsy devices market in 2023, accounting for 43.1% of the total revenue share.
- The U.S. alone contributed 34.6% to the global market, reflecting strong healthcare infrastructure, high adoption of advanced diagnostic technologies, and significant investment in cancer research.
- In terms of product, needle-based biopsy guns dominated the market in 2023 with the largest share of 43.1%.
- due to their precision, ease of use, and widespread clinical adoption. Additionally, the biopsy needle segment is expected to witness significant growth over the forecast period, driven by increasing demand for accurate tissue sampling in oncology and other medical applications.
Order a free sample PDF of the Biopsy Devices Market Intelligence Study, published by Grand View Research.
Market Size & Forecast
- 2023 Market Size: USD 2.25 Billion
- 2030 Projected Market Size: USD 3.64 Billion
- CAGR (2024-2030): 7.1%
- North America: Largest market in 2023
Key Companies & Market Share Insights
Some players in the market include Cardinal Health Inc., Hologic, Inc., and Danaher Corporation, and others. These players are majorly engaged in R&D to develop technologically advanced products to help them retain a strong position in the market. For instance, in August 2022, Devicor Medical Products, Inc. introduced the Mammotome DualCore Dual Stage Core Biopsy System, which is expected to help the company in advancing its biopsy device portfolio.
- Cardinal Health, Inc. is a global healthcare services and products company operating majorly in two segments: Pharmaceutical and Medical. The company also engages in the production of minimally invasive biopsy devices such as fine needle core biopsy (FNCB), bone marrow biopsy & aspiration needles, and Tissue Biopsy Kits.
- Hologic, Inc. is a global company engaged in developing, manufacturing, and supplying medical imaging systems, diagnostic products, and surgical products, including biopsy devices. The company has introduced advanced biopsy devices such as the Eviva Breast Biopsy system, and Brevera breast biopsy system to gain a competitive edge.
Key Players
- Cardinal Health Inc.
- Hologic, Inc.
- Danaher Corporation
- CONMED Corporation
- Cook Medical
- DTR Medical
- INRAD, Inc.
- Devicor Medical Products Inc.
- Gallini Srl
- TransMed7, LLC.
Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.
Conclusion
The global biopsy devices market is poised for steady growth through 2030, driven by the rising prevalence of cancer, increasing preference for minimally invasive procedures, and expanding healthcare infrastructure in emerging economies. North America, particularly the U.S., remains the largest market, supported by advanced diagnostic technologies and research initiatives. Needle-based biopsy devices dominate due to their accuracy and clinical adoption, while the biopsy needle segment is projected to experience significant growth. With increasing cancer incidence and heightened awareness of early diagnosis, the demand for precise, efficient, and minimally invasive biopsy solutions is expected to expand globally, ensuring sustained market growth.
